BiVictriX Therapeutics, an emergent powerhouse in the biotechnology industry, is pioneering an innovative approach to engineer safer, yet more potent cancer treatments. Their groundbreaking Bi-Cygni® therapeutics have been meticulously crafted to be highly selective for specific types of cancer. This selective approach allows for more potent doses, aiding in the aggressive obliteration of cancer cells without the debilitating side effects typically associated with cancer treatment. Utilising cutting-edge techniques, BiVictriX is identifying specific combinations of targets for both solid and liquid tumours.
The founder behind the Bi-Cygni® concept is Tiffany Thorn, CEO of BiVictriX. Leveraging her past experiences as a clinician involved in diagnosing blood cancers, Tiffany brought this innovative concept to life. Since the company's establishment in 2016, Tiffany has been the driving force behind BiVictriX, reaching crucial business milestones and raising an impressive £10 million in investment. She spearheaded the successful Initial Public Offering (IPO) of the company on the London Stock Exchange’s AIM market in August 2021.
Tiffany's leadership skills are further fortified by her extensive background in the Antibody-Drug Conjugate (ADC) sector. She has held pivotal management roles at ADC-specialist firm ADC Bio Ltd (now Sterling Pharma Solutions), and gained invaluable direct clinical experience from her time within the NHS. As a qualified HCPC-registered Clinical Immunologist trained at Manchester Royal Infirmary and Preston Royal Hospital, UK, Tiffany’s contributions to the healthcare sector have been recognised with the “NHS England’s Chief Scientific Officer’s Rising Star Award.” This prestigious accolade highlights her unwavering commitment to enhancing healthcare by fortifying the vital connections between the UK’s healthcare system and the biotech industry.
.svg)
.svg)
